Our Latest Scientific Advances in the Management on CMPA
-
Article Can Human Milk Oligosaccharides modulate the allergic response and improve the management of Cow’s Milk Protein Allergy?
This symposium took place on the 1st December 2022, as part of the European Academy of Allergy and Clinical Immunology (EAACI) FAAM-EUROBAT Digital Conference Chairperson:Alexandra Santos1,2Speakers:Liam O’Mahony,3 Claire Boulangé,4 Anna Nowak-W
-
Article EMJ Allergy & Immunology 6.1 2021
INFOWelcome to the latest issue of EMJ Allergy & Immunology! This eJournal brings you the most up-to-date research and fascinating findings from this year’s virtual EAACI Congress. Alongside the breaking news from this event, we are pleased to sh
Microbiome and Immunity
-
Article Can Human Milk Oligosaccharides modulate the allergic response and improve the management of Cow’s Milk Protein Allergy?
This symposium took place on the 1st December 2022, as part of the European Academy of Allergy and Clinical Immunology (EAACI) FAAM-EUROBAT Digital Conference Chairperson:Alexandra Santos1,2Speakers:Liam O’Mahony,3 Claire Boulangé,4 Anna Nowak-W
-
Article EMJ Allergy & Immunology 6.1 2021
INFOWelcome to the latest issue of EMJ Allergy & Immunology! This eJournal brings you the most up-to-date research and fascinating findings from this year’s virtual EAACI Congress. Alongside the breaking news from this event, we are pleased to sh
-
Article Infants with Cow’s Milk Protein Allergy (CMPA) fed human milk oligosaccharides have fewer infections
The CINNAMON trial compared Althéra®, supplemented with the two HMO, 2’fucosyl-lactose (2’FL) and lacto-N-neotetraose (LNnT)) and with a reduced protein content (2.2g/100kcal), to Althéra® without HMO and a higher protein content (2.5g/100kcal) in infants with CMPA. The primary outcome was growth (weight gain)
Latest News About CoMiSS™
-
Microbiome and Immunity Can Human Milk Oligosaccharides modulate the allergic response and improve the management of Cow’s Milk Protein Allergy?
This symposium took place on the 1st December 2022, as part of the European Academy of Allergy and Clinical Immunology (EAACI) FAAM-EUROBAT Digital Conference Chairperson:Alexandra Santos1,2Speakers:Liam O’Mahony,3 Claire Boulangé,4 Anna Nowak-W
-
Microbiome and Immunity EMJ Allergy & Immunology 6.1 2021
INFOWelcome to the latest issue of EMJ Allergy & Immunology! This eJournal brings you the most up-to-date research and fascinating findings from this year’s virtual EAACI Congress. Alongside the breaking news from this event, we are pleased to sh
-
CoMiSS™ WEBINARS Nestlé’s Human Milk Oligosaccharide blend positively shapes the gut microbiome of infants with Cow’s Milk Protein Allergy
Lausanne, Switzerland [17 October 2020] -- Nestlé Health Science and Clinical Microbiomics (Copenhagen, Denmark) presented new evidence from the CINNAMON study at the FAAM-EUROBAT Digital 2020 Meeting. The new data show that the addition of two Human Milk Oligosaccharides (HMO; 2’fucosyl-lactose (2’FL) and lacto-N-neotetraose (LNnT)) to the whey-based, extensively hydrolyzed formula, Althéra®, positively shapes the gut microbiome of infants with cow’s milk protein allergy (CMPA). Evidence presented previously confirmed that Althéra® with the two HMO is safe, hypoallergenic, reduces respiratory tract infections, supports normal growth and is well tolerated in infants with CMPA.1-4
